201 results on '"Boguniewicz A"'
Search Results
2. Dupilumab Consistently Reduces CCL-17 (TARC) in Patients with Atopic Dermatitis Across All Age Groups
3. Dupilumab Improves Skin Lipid Barrier in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis
4. Cutaneous Ceramide Synthase 1 (CERS1) Gene Expression is a Biomarker of Staphylococcus aureus Abundance and Severity of Atopic Dermatitis
5. Topical Treatments for Atopic Dermatitis: Systematic Review and Network Meta-Analysis of Randomized Trials
6. Lebrikizumab Maintains Improvements in the Patient-Oriented Eczema Measure Through 2 Years of Treatment in Patients With Moderate-to-Severe Atopic Dermatitis
7. Systemic Treatments for Atopic Dermatitis: Systematic Review and Network Meta-Analysis of Randomized Trials
8. Tapinarof Validates the Aryl Hydrocarbon Receptor as a Therapeutic Target: A Clinical Review
9. The role of Janus kinase signaling in the pathology of atopic dermatitis
10. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment
11. Dupilumab inhibits vascular leakage of blood proteins into atopic dermatitis skin
12. Dupilumab Reduces Inflammatory Biomarkers in Patients Aged 6 Months to 18 Years With Moderate-to-Severe or Severe Atopic Dermatitis
13. Dupilumab Treatment Reduces Total IgE Levels in Patients 6 Months and Older with Moderate-to-Severe Atopic Dermatitis
14. Dupilumab Efficacy in Children With Atopic Dermatitis Aged 6 Months to 5 Years With and Without Atopic Comorbidities
15. Efficacy of Lebrikizumab in Patients With Atopic Dermatitis and Atopic Comorbidities: Pooled Results From Two Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2)
16. Effect of Abrocitinib and Dupilumab on Eosinophil Levels in Patients With Moderate-to-Severe Atopic Dermatitis and With or Without Comorbid Asthma or Allergic Rhinitis: A Post Hoc Pooled Analysis of JADE COMPARE and JADE DARE
17. Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms
18. Dupilumab Treatment Reduces Total IgE Levels in Patients 6 Months and Older with Moderate-to-Severe Atopic Dermatitis
19. Efficacy of Lebrikizumab in Patients With Atopic Dermatitis and Atopic Comorbidities: Pooled Results From Two Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2)
20. Dupilumab Reduces Inflammatory Biomarkers in Patients Aged 6 Months to 18 Years With Moderate-to-Severe or Severe Atopic Dermatitis
21. Dupilumab Efficacy in Children With Atopic Dermatitis Aged 6 Months to 5 Years With and Without Atopic Comorbidities
22. Dupilumab treatment significantly improves skin barrier function in adult and adolescent patients with moderate to severe atopic dermatitis
23. Are skin microbes with lantibiotic biosynthesis genes reduced in atopic dermatitis subjects who are culture positive for Staphylococcus aureus?
24. Efficacy of Abrocitinib Rescue Therapy in the Phase 3 Study JADE REGIMEN
25. Effect of Dupilumab on the Host-Microbe Interface in Atopic Dermatitis
26. Dupilumab treatment significantly improves skin barrier function in adult and adolescent patients with moderate to severe atopic dermatitis
27. Efficacy of Abrocitinib Rescue Therapy in the Phase 3 Study JADE REGIMEN
28. Dupilumab Improves Signs And Symptoms Of Severe Atopic Dermatitis In Children Aged 6–11 Years With And Without Comorbid Asthma
29. Depth and Rapidity of Response With Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis (AD) in JADE COMPARE
30. Dupilumab Improves Signs And Symptoms Of Severe Atopic Dermatitis In Children Aged 6–11 Years With And Without Comorbid Asthma
31. Depth and Rapidity of Response With Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis (AD) in JADE COMPARE
32. Efficacy of Dupilumab in Adolescents With Moderate-to-Severe Atopic Dermatitis With and Without Comorbid Asthma: Subgroup Analysis From a Phase 3 Trial
33. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions”
34. Efficacy of Baricitinib in Patients with Atopic Dermatitis and Atopic Comorbidities: Results of Pooled Data from 2 Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-week Trials (BREEZE-AD1 and BREEZE-AD2)
35. Efficacy of Dupilumab in Adolescents With Moderate-to-Severe Atopic Dermatitis With and Without Comorbid Asthma: Subgroup Analysis From a Phase 3 Trial
36. Nonlesional Atopic Dermatitis Skin Shows Alterations in Langerhans Cells in Close Proximity to Tight Junction Fragmentation
37. Measurement properties of Hospital Anxiety and Depression Scale used in atopic dermatitis in adults
38. Dupilumab Improves Outcomes of Concurrent Asthma and Chronic Sino-Nasal Conditions in Patients With Atopic Dermatitis—a Pooled Analysis of Four Phase 3 Studies (LIBERTY AD SOLO 1 & 2, CHRONOS, and CAFÉ)
39. Nonlesional Atopic Dermatitis Skin Shows Alterations in Langerhans Cells in Close Proximity to Tight Junction Fragmentation
40. Dupilumab Improves Outcomes of Concurrent Asthma and Chronic Sino-Nasal Conditions in Patients With Atopic Dermatitis—a Pooled Analysis of Four Phase 3 Studies (LIBERTY AD SOLO 1 & 2, CHRONOS, and CAFÉ)
41. Recent insights into atopic dermatitis and implications for management of infectious complications
42. Cytokine modulation of atopic dermatitis filaggrin skin expression
43. Patients with adult- and late childhood-onset atopic dermatitis report a higher burden of disease severity than patients with early childhood-onset atopic dermatitis.
44. Staphylococcus Aureus -Culture Positivity Observed In Adults With Atopic Dermatitis Is Most Indicative Of An Increased Absolute and Relative Abundance Of S. Aureus and Not Reduced Biodiversity
45. Defective killing of Staphylococcus aureus in atopic dermatitis is associated with reduced mobilization of human β-defensin-3
46. Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines
47. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report
48. 10. Atopic dermatitis
49. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology
50. Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.